Clinical Trials Logo

EGFR Activating Mutation clinical trials

View clinical trials related to EGFR Activating Mutation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04764214 Completed - NSCLC Stage IV Clinical Trials

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

This study is an open-label, single-arm phase 2 trial to evaluate the efficacy and safety of stereotactic radiotherapy (SRT) for patients with oligo-residual NSCLC after 3rd generation EGFR-TKIs.

NCT ID: NCT03544814 Completed - Lung Adenocarcinoma Clinical Trials

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Start date: January 1, 2015
Phase: Phase 2
Study type: Interventional

To compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential treatment after patients gradually progressed from first-line EGFR-TKI treatment. Patients who had gradual progression and EGFR-T790M mutation-negative were randomly divided into two groups: in concurrent group, patients were treated with pemetrexed plus cisplatin along with the same EGFR-TKI; in sequential group, patients continued with EGFR-TKI until the disease progressed again according to the RECIST criteria, and then switched to chemotherapy. We evaluated progression-free survival (PFS) and overall survival (OS) time of patients. For sequential group, PFS was PFS1 (gradual progression to discontinue EGFR-TKI) plus PFS2 (chemotherapy alone).